ConductScience.org, home

Paper39273139

Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.

Ishikawa K and 9 others. Int J Mol Sci, 2024. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas. Papers, record 39273139. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39273139

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.75, provisional
iCite
Revised in PubMed
2024-11-05
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ishikawa KKenichiro
2Suzuki HHiroyukihttps://orcid.org/0000-0003-2646-5132
3Ohishi TTomokazuhttps://orcid.org/0000-0002-9039-4474
4Li GGuanjiehttps://orcid.org/0000-0002-7984-5414
5Tanaka TTomohiro
6Kawada MManabuhttps://orcid.org/0000-0001-9348-4240
7Ohkoshi AAkirahttps://orcid.org/0000-0003-0652-7041
8Kaneko MKMika Khttps://orcid.org/0000-0002-4158-9208
9Katori YYukio
10Kato YYukinarihttps://orcid.org/0000-0001-5385-8201

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hyaluronan ReceptorsMajor topic
Mouth NeoplasmsMajor topic
Antibodies, MonoclonalMajor topic
Xenograft Model Antitumor AssaysMajor topic
Carcinoma, Squamous CellMajor topic
Animals
Mice
Humans
Cell Line, Tumor
CHO Cells
Cricetulus
Antineoplastic Agents, Immunological
Antibody-Dependent Cell Cytotoxicity
Cell Proliferation
Mice, Inbred BALB C

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
24am0521010 (to Y.Kato), JP23ama121008 (to Y.Kato), JP23am0401013 (to Y.Kato), JP23bm1123027 (to Y.Kato), and JP23ck0106730 (to Y.Kato)Japan Agency for Medical Research and DevelopmentPubMed
22K06995 (to H.S.), 21K20789 (to T.T.), 21K07168 (to M.K.K.), and 22K07224 (to Y.Kato)Japan Society for the Promotion of SciencePubMed

Source PubMed

Download CSV of grants

References80

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126074915CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells.Front Immunol2015https://conductscience.org/library/papers/26074915PubMed
21707342A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.Cell1991https://conductscience.org/library/papers/1707342PubMed
337176118A Novel Anti-CD44 Variant 3 Monoclonal Antibody C44Mab-6 Was Established for Multiple Applications.Int J Mol Sci2023https://conductscience.org/library/papers/37176118PubMed
423694705Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma.Semin Immunol2013https://conductscience.org/library/papers/23694705PubMed
512464636CD44 is required for two consecutive steps in HGF/c-Met signaling.Genes Dev2002https://conductscience.org/library/papers/12464636PubMed
67689929Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa.Cancer Res1993https://conductscience.org/library/papers/7689929PubMed
727081038Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.Oncotarget2016https://conductscience.org/library/papers/27081038PubMed
834424761Development of a Novel Epitope Mapping System: RIEDL Insertion for Epitope Mapping Method.Monoclon Antib Immunodiagn Immunother2021https://conductscience.org/library/papers/34424761PubMed
928923838Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT.Mol Cancer Res2017https://conductscience.org/library/papers/28923838PubMed
1021187443Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.J Immunol2011https://conductscience.org/library/papers/21187443PubMed
117532175Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon.J Cell Biol1995https://conductscience.org/library/papers/7532175PubMed
1224607406CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.Cell Stem Cell2014https://conductscience.org/library/papers/24607406PubMed
1337504249Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody C44Mab-18 for Immunohistochemical Analysis against Oral Squamous Cell Carcinomas.Curr Issues Mol Biol2023https://conductscience.org/library/papers/37504249PubMed
1437185762A Novel Anti-CD44 Variant 9 Monoclonal Antibody C44Mab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers.Curr Issues Mol Biol2023https://conductscience.org/library/papers/37185762PubMed
1528920587Complement in cancer: untangling an intricate relationship.Nat Rev Immunol2018https://conductscience.org/library/papers/28920587PubMed
1630396933Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.Anticancer Res2018https://conductscience.org/library/papers/30396933PubMed
1711992408Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.Int J Cancer2002https://conductscience.org/library/papers/11992408PubMed
1817062682A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.Clin Cancer Res2006https://conductscience.org/library/papers/17062682PubMed
1938460519Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies.Structure2024https://conductscience.org/library/papers/38460519PubMed
2024410905Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis.BMC Cancer2014https://conductscience.org/library/papers/24410905PubMed

See all 80 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
40688499Development of a specific anti-human EphA3 monoclonal antibody, Ea3Mab-20, for flow cytometry.Biochem Biophys Rep2025https://conductscience.org/library/papers/40688499PubMed
40688054Hyaluronic Acid-Functionalized Bismuth Vanadate/Molybdenum Disulfide Nanoheterojunctions Achieve Efficient Phototherapy of Hypoxic Tumor.Biomater Res2025https://conductscience.org/library/papers/40688054PubMed
40236294Development of an anti-human EphA2 monoclonal antibody Ea2Mab-7 for multiple applications.Biochem Biophys Rep2025https://conductscience.org/library/papers/40236294PubMed
40028039A novel anti-mouse CCR7 monoclonal antibody, C7Mab-7, demonstrates high sensitivity in flow cytometry, western blot, and immunohistochemistry.Biochem Biophys Rep2025https://conductscience.org/library/papers/40028039PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39273139

GET https://conductscience.org/api/papers/v1/39273139/references?page=2